stockrow
Friday 6 November 2026
Export TTOO’s income statement to Excel — free account
T2 Biosystems, Inc.
TTOO Healthcare Diagnostics & Research
T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022.
0.00
0.00
NaN
Follow TTOO
Alert me
| Older periods | Dec '23 | Mar '24 | Jun '24 | Sep '24 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 1 | 3 | 2 |
| 147.96% | 104.14% | 228.08% | 277.61% | ||
| (144.89%) | (158.80%) | (164.01%) | (140.00%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
170.88% | 116.79% | 662.39% | 326.10% | |
Average Days of Receivables |
72.06 | 80.77 | 66.08 | 96.66 | |
Free Cash Flow per Share |
(18.52) | (9.20) | (3.10) | (2.05) | |
Free Cash Flow |
(48.33) | (46.88) | (43.73) | (36.59) | |
Capital Expenditures |
(0.19) | — | — | — | |
| Other line items | |||||
Cash ROIC |
391.41% | 148.52% | 2,647.28% | 380.10% | |
Accounts Receivable Turnover |
4.02 | 4.93 | 5.42 | 4.84 | |
Accounts Payable Turnover |
10.88 | 6.21 | 6.83 | 5.12 | |
Inventory Turnover |
3.38 | 3.24 | 2.82 | 3.35 | |
Average Days of Payables |
36.28 | 44.24 | 45.95 | 113.24 | |
Days of Inventory on Hand |
114.49 | 109.48 | 140.86 | 102.88 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
196.76% | 186.78% | 180.26% | 168.27% | |
Selling, General and Administrative Expense of Revenue |
345.20% | 338.20% | 327.28% | 297.56% | |
Share Based Compensation of Revenue |
60.49% | 57.32% | 47.57% | 35.78% | |
Interest Coverage |
(9.30) | (9.72) | (11.46) | (13.07) | |
Operating CF/Net income |
0.96 | 1.03 | 0.91 | 0.85 | |
Depreciation/Fixed assets |
0.52 | 0.41 | 0.30 | 0.18 | |
Capex/Depreciation |
(0.22) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
2.76 | 1.41 | 0.51 | 0.43 | |
Operating CF per Share |
(18.44) | (9.20) | (3.10) | (2.05) | |
Capex per Share |
(0.07) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026